Johnson & Johnsons arrangement around Stelara ahead of ustekinumab biosimilar entry included an authorized generic component that gave certain formulary-preferred distributors access to the reference biologic at a substantially discounted price, complicating the formulary economics for non-authorized biosimilar entrants
doi: 10.3389/fpsyt.2023.1153648 Received 29 January 2023 Accepted 12 April 2023 Published 05 May 2023 Volume 14 - 2023 Edited by Sarah Tosato, University of Verona, Italy Reviewed by Najmeh Shahini, Golestan University of Medical Sciences, Iran
Over weeks and months, this visual record shows you exactly which areas are overused and which have been resting
L-Glutamine: Foundational Fuel for Gut and Muscle Health L-Glutamine by SFI Health provides a pure, free-form source of the most abundant amino acid in the body
Coz Yataco and Simpson, 2020